To main content (press Enter)
650bd4b8a58539c243eb753066bd6b17 jpg

Cellistic's platform enables faster allogeneic cell therapies manufacturing

Cellistic reveals groundbreaking iPSC-based platforms to speed-up off-the-shelf allogeneic cell therapy development and manufacturing.

While the initial proof points in cell therapy have been made largely by autologous regimens, for cell therapy to play a broad role in human health we need to greatly reduce the price per dose and time to development of products.” said Gustavo Mahler, Cellistic CEO, “We believe that Cellistic’s iPSC platform-based approach unlocks the ability to significantly reduce development time and provides a reliable manufacturing process at a scale in very cost effective terms. Our platforms enable cell therapies to be developed faster and in a much more affordable way”

Providing therapeutic developers with high quality and reproduceable off-the shelf cell therapies

Stefan Braam, Cellistic’s Founder and CTO, shared insights about the platform. “We’ve made significant investments to build technology platforms with the mission of significantly reducing the time and providing high quality and reproduceable off-the shelf cell therapies to the market. Our therapeutic partners can come to us with their proprietary edits and target product profiles, we can plug them into our platforms and get them into the clinic faster than ever. There is no process transfer that acts as a hurdle to the development timeline, as there would be if a contract manufacturer was engaged.

A turn-key development support for autologous and allogeneic cell therapies production

Cellistic’s Pulse™ Cell Line and Echo™ Cell Therapy Manufacturing platforms are built on induced pluripotent stem cell (iPSC) technology which is the most robust and cost-effective way to build off-the-shelf allogeneic cell therapies. In addition to these platforms, Cellistic provides partners with turn-key development support via their new GMP facility located on their campus in Mont-Saint-Guibert, Belgium.

We are already working with autologous and allogeneic cell therapy partners to build their next generation off-the-shelf iPSC-based product leveraging our platforms. We can uniquely accelerate and simplify their journey to the clinic with the combination of our platforms, our purpose built GMP facility, and the expertise of our team which has successfully manufactured hundreds of immuno-oncology cell therapy clinical batches." said Mahler. For investors within this space, it also provides a stronger foundation to reach the patient with a viable product in shorter time and less cost.

Interested in updates on our
insights, news and testimonials?